• Customer PortalResource Center
  • bioMérieux weltweit
    Finden Sie alle unsere Standorte
    Error | BioMérieux directory

    Error

    The website encountered an unexpected error. Please try again later.
z.B. 11/23/2024
z.B. 11/23/2024

bioMérieux – 2015 Financial Results

02 März, 2016

BioFire Receives FDA Clearance for FilmArray® Torch with FilmArray® Respiratory Panel and Submits Special 510(k) Applications for Use with additional FilmArray® Panels

25 Februar, 2016

FilmArray® Torch delivers high throughput, radically smaller footprint

Fourth-Quarter 2015 Business Review

21 Januar, 2016

BioFire Submits Special 510(k) Application to the FDA for the use of FilmArray® Torch, the New High Throughput FilmArray® System with FilmArray® Respiratory Panel

12 Januar, 2016

FilmArray® Torch delivers high throughput, radically smaller footprint

BioFire’s FilmArray® Meningitis/Encephalitis Panel gets CE marked

11 Januar, 2016

FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform 

bioMérieux acquires Applied Maths and enhances its bioinformatics capabilities with cutting-edge expertise and solutions for the smart use of complex biological data

05 Januar, 2016

bioMérieux and Illumina announce the launch of bioMérieux EpiSeq™, a revolutionary Next-Generation Sequencing service for epidemiological monitoring of bacterial infections

15 Dezember, 2015

BioFire Diagnostics receives a de novo clearance by the FDA for the FilmArray® Meningitis/Encephalitis panel 

04 November, 2015

FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform.continuing its extremely favorable business momentum

BioFire Diagnostics receives a de novo clearance by the FDA for the FilmArray® Meningitis/Encephalitis panel continuing its extremely favorable business momentum

09 Oktober, 2015

FilmArray® expanded menu, with a fourth panel, is the largest available on a molecular biology multiplex platform

bioMérieux and Astute Medical sign a global agreement to develop and market NephroCheck® Test for VIDAS®, an assay to assess the risk of developing acute kidney injury 

26 Februar, 2015